Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 2, 2012, Pages 471-477

  Jayachandran, Priya ^a   Pai, Reetesh K ^b   Quon, Andrew ^a   Graves, Edward ^a   Krakow, Trevor E ^a   La, Trang ^a   Loo Jr , Billy W ^a   Koong, Albert C ^a   Chang, Daniel T ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Esophageal cancer; PET; Positron emission tomography; Treatment response

Indexed keywords

ESOPHAGEAL CANCER; MEDICAL RECORD; OVERALL SURVIVAL; PATHOLOGIC RESPONSE; PET SCAN; POSITRON EMISSION TOMOGRAPHY SCANNING; STANDARDIZED UPTAKE VALUES; SURGICAL RESECTION; TREATMENT RESPONSE; TUMOR REGRESSION GRADES; TUMOR VOLUMES;

DISEASES; PATHOLOGY; PATIENT MONITORING; PATIENT TREATMENT; POLYETHYLENE TEREPHTHALATES; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84865627144     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.12.029     Document Type: Article

References (27)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J. Tepper, M.J. Krasna, and D. Niedzwiecki Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 J Clin Oncol 26 2008 1086 1092
3. Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. Presented at the 2010 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2010.
4. M. Stahl, M. Stuschke, and N. Lehmann Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310 2317
5. L. Bedenne, P. Michel, and O. Bouche Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 J Clin Oncol 25 2007 1160 1168
6. H. Ariga, K. Nemoto, and S. Miyazaki Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus Int J Radiat Oncol Biol Phys 75 2009 348 356
7. P. Flamen, E. Van Cutsem, and A. Lerut Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer Ann Oncol 13 2002 361 368
8. S.G. Swisher, J. Erasmus, and M. Maish 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma Cancer 101 2004 1776 1785
9. A.A. Konski, J.D. Cheng, and M. Goldberg Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma Int J Radiat Oncol Biol Phys 69 2007 358 363
10. H.A. Wieder, K. Ott, and F. Lordick Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction Eur J Nucl Med Mol Imaging 34 2007 1925 1932
11. I. Higuchi, T. Yasuda, and M. Yano Lack of fluorodeoxyglucose F18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma J Thorac Cardiovasc Surg 136 2008 205 212 212, e201-e203
12. B.M. Smithers, G.C. Couper, and J.M. Thomas Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus Dis Esophagus 21 2008 151 158
13. F. Lordick, K. Ott, and B.J. Krause PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial Lancet Oncol 8 2007 797 805
14. P. Lee, J.G. Bazan, and P.W. Lavori Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer Clin Lung Cancer Epub 2011 Jun 22
15. J.D. Murphy, T.H. La, and K. Chu Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer Int J Radiat Oncol Biol Phys 80 2011 514 521
16. D. Schellenberg, A. Quon, and A.Y. Minn 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy Int J Radiat Oncol Biol Phys 77 2010 1420 1425
17. W. Huang, T. Zhou, and L. Ma Standard uptake value and metabolic tumor volume of (18)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer Eur J Nucl Med Mol Imaging 38 2011 1628 1635
18. S.H. Hyun, J.Y. Choi, and Y.M. Shim Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma Ann Surg Oncol 17 2010 115 122
19. AJCC Cancer Staging Manual 7th ed. 2010 Springer Chicago, IL
20. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
21. R.V. Scheer, A.J. Fakiris, and P.A. Johnstone Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer Int J Radiat Oncol Biol Phys 80 2011 996 1001
22. W.A. Weber, K. Ott, and K. Becker Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
23. E.A. Levine, M.R. Farmer, and P. Clark Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer Ann Surg 243 2006 472 478
24. J.F. Bruzzi, S.G. Swisher, and M.T. Truong Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy Cancer 109 2007 125 134
25. J.B. Roedl, R.R. Colen, and N.S. Holalkere Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT: Comparison to histopathologic and clinical response evaluation Radiother Oncol 89 2008 278 286
26. A.M. Monjazeb, G. Riedlinger, and M. Aklilu Outcomes of patients with esophageal cancer staged with [(1)F]fluorodeoxyglucose positron emission tomography (FDG-PET): Can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28 2010 4714 4721
27. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 2009 122S 150S